Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, has announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of US$28.00 per share, before deducting underwriting discounts and commissions. In addition, Guardant Health has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Guardant Health, are expected to be US$350.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 25, 2023, subject to the satisfaction of customary closing conditions.
Latham & Watkins LLP represents Guardant Health in the offering, with a capital markets team led by Orange County partners Shayne Kennedy and Drew Capurro, with associates Eric Hanzich, Gregory Van Buiten, AJ Blair, and Azzam Chaudhry. Advice was also provided on tax matters by Bay Area partners Kirt Switzer and Grace Lee, with associates Alexander Farris and Rasha Suleiman; and on regulatory and healthcare compliance matters by Washington, D.C. partner Elizabeth Richards, Bay Area partner Betty Pang, and Washington, D.C. counsel Chad Jennings.